EUS-RFA for Unresectable Pancreatic Cancer

Status Completed

Clinical Trial Summary

The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.

Clinical Trial Description

evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04310111
Study type	Interventional
Source	First People's Hospital of Hangzhou
Contact
Status	Completed
Phase	N/A
Start date	March 1, 2020
Completion date	August 25, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05209074` - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma	Phase 1
Recruiting	`NCT04969731` - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT04927780` - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT05048524` - Peri-operative SLOG for Localized Pancreatic Cancer	Phase 2
Terminated	`NCT04042480` - A Study of SGN-CD228A in Advanced Solid Tumors	Phase 1
Completed	`NCT03257150` - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer	N/A
Terminated	`NCT04400903` - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting	`NCT05462717` - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Phase 1
Active, not recruiting	`NCT03267316` - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Phase 1/Phase 2
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04046887` - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)	Phase 1
Recruiting	`NCT05964621` - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting	`NCT04827953` - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Recruiting	`NCT05977322` - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting	`NCT04862260` - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma	Early Phase 1
Active, not recruiting	`NCT04853017` - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors	Phase 1
Completed	`NCT03770117` - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed	`NCT02259114` - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	Phase 1